AKT1 and neoplasm: ,26,27 Monotherapy with PI3K-AKT pathway inhibitors has shown minimal activity in clinical trials in prostate cancer; however, combination therapies targeting this pathway have demonstrated enhanced anti-tumor effects, suggesting the potential of strategic combination treatments.28